| ID | 1267 |
| Name of the vaccine | COVAXIS |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 10 to 14 years |
| Description of the vaccine | Tdap vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Germany |
| Year of manufacture | 2007 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Given as 5th or 6th dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For tetanus and acellular pertussis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00304265 |
| Reference | https://www.researchgate.net/publication/47659560_Tdap5_Vaccine_CovaxisR |
| Other name | NA |
| Additional Links | NA
|